跳至主要内容
临床试验/NCT06011824
NCT06011824已完成不适用

Megakaryocytes and Platelets, Harmful or Helpful in Breast Cancer Cell Metastasis

Mayo Clinic1 个研究点 分布在 1 个国家目标入组 23 人开始时间: 2023年8月29日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Mayo Clinic
入组人数
23
试验地点
1
主要终点
Platelet Counts

研究概览

简要总结

Determining if Megakaryocytes and Platelets are Harmful or Helpful in Breast Cancer Cell Metastasis

详细描述

The purpose of this study is to determine how megakaryocytes (cells in the bone marrow responsible for making platelets, which are necessary for blood clotting) affect the survival and growth/division patterns of breast cancer stem cells, and the effects of breast cancer cells on megakaryocyte survival and function. Through chart review, the study team will look at the relationship between different blood components and different breast cancer diagnoses.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Cohort 1-Biopsy negative
  • Females age 18 and above
  • Cohort 2-Biopsy positive for carcinoma in situ (ductal, lobular, or other)
  • Females age 18 and above
  • Any subtype of breast cancer
  • Cohort 3-Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)
  • Females age 18 and above
  • Any subtype of breast cancer
  • Have no distant metastases
  • Cohort 4-Stage 4 Metastatic Disease
  • Females age 18 and above
  • Any subtype of breast cancer

排除标准

  • Previous diagnosis with a known platelet disorder such as: Bernard Soulier disease, Jacobsen syndrome, Lowe syndrome, Thrombocytopenia, Thrombotic thrombocytopenic pupura, Von Willebrand disease, or the equivalent. Any condition in which antiplatelet or anticoagulant therapy with one of the following medications is being prescribed: Clopidogrel (Plavix), Warfarin (Coumadin or Jantoven), Prasugrel (Effient), or Ticagrelor (Brilinta).
  • Cohort 1-Biopsy negative
  • Females less than age 18
  • Cohort 2-Biopsy positive for carcinoma in situ (ductal, lobular, or other)
  • Females less than age 18
  • Currently undergoing neoadjuvant therapy
  • Cohort 3-Biopsy positive for Stage 1, 2, or 3 invasive carcinoma (ductal, lobular, or other)
  • Females less than age 18
  • Presence of distant metastases
  • Currently undergoing neoadjuvant therapy
  • Cohort 4-Stage 4 Metastatic Disease
  • Females less than age 18
  • Currently undergoing neoadjuvant therapy
  • Less than 30 days from last adjuvant treatment for Stage I-III Breast Cancer (may be on Trastuzumab, Pertuzumab, or endocrine therapy only for maintenance therapy from their prior breast cancer diagnosis)

结局指标

主要结局

Platelet Counts

时间窗: Baseline

Measure of the number of platelets in the blood, reported as platelets per microliter of blood.

次要结局

  • Mean Corpuscular Volume (MCV)(Baseline)
  • Lymphocyte to neutrophil ratio(Baseline)
  • Levels of tumor educated platelets(Baseline)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验